Principles of vaccine design-Lessons from nature

Vaccine

Volumn 28, Issue SUPPL. 3, 2010, Pages

  Zepp, Fred ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

History; Immunogenicity; Vaccinology

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT VACCINE; ROTAVIRUS VACCINE; VACCINE; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; ANTIGEN; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELLULAR IMMUNITY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUBERCULOSIS; UTERINE CERVIX CANCER; VACCINATION; HISTORY; IMMUNE SYSTEM; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANTIGENS; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; VACCINES;

EID: 77955647584     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.020     Document Type: Review

References (112)

1. Plotkin S.L., Plotkin S.A. A short history of vaccination. Vaccines 2008, 1-16. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
2. Fenner F., Henderson D.A., Arita I., Ježek Z., Ladnyi I.D. Smallpox and its eradication 1988, World Health Organisation, Geneva, Switzerland.
3. World Health Organisation. Fact sheet no. 114-Poliomyelitis, Available from: URL: ; January 2008 [last accessed 2010 May 25]. http://www.who.int/mediacentre/factsheets/fs114/en/.
4. Ellis R.W. Technologies for making new vaccines. Vaccines 2008, 1335-1356. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
5. Bloch K.C. Infectious diseases. Pathophysiology of disease: an introduction to clinical medicine 2006, 59-88. McGraw-Hill Professional, New York. 5th ed. S.J. McPhee, V.R. Lingappa, W.F. Ganong (Eds.).
6. Moser M., Leo O. Key concepts in immunology. Vaccine 2010.
7. Worboys M. Vaccines: conquering untreatable diseases. BMJ 2007, 334(Suppl. 1):s19.
8. Girard M.P., Steele D., Chaignat C.L., Kieny M.P. A review of vaccine research and development: human enteric infections. Vaccine 2006, 24(15):2732-2750.
9. Edwards K.M., Decker M.D. Pertussis vaccines. Vaccines 2008, 467-518. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
10. Bridges C.B., Katz J.M., Levandowski R.A., Cox N.J. Inactivated influenza vaccines. Vaccines 2008, 259-290. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
11. World Health Organisation. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries. Weekly Epidemiological Report 28, 2003; 78:241-50. Available from: URL: [last accessed 2010 May 25]. http://www.who.int/wer/2003/wer7828/en/index.html.
12. World Health Organisation. Rabies vaccines WHO position paper. Weekly Epidemiological Report 49/50, 2007a;82:425-435. Available from: URL: [last accessed 2010 May 25]. http://www.who.int/wer/2007/wer8249_50/en/index.html.
13. Tauber E., Dewasthaly S. Japanese encephalitis vaccines-needs, flaws and achievements. Biol Chem 2008, 389(5):547-550.
14. Demicheli V., Debalini M.G., Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst Rev 2009, 1. CD000977.
15. Fiore A.E., Feinstone F.M., Bell B.P. Hepatitis A vaccines. Vaccines 2008, 177-204. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
16. Sutter R.W., Kew O.M., Cochi S.L. Poliovirus vaccine-live. Vaccines 2008, 631-686. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
17. Gershon A.A., Takahashi M., Seward J.F. Varicella vaccines. Vaccines 2008, 915-958. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
18. Griffin D.E., Pan C.H. Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol 2009, 330:191-212.
19. Vesikari T., Sadzot-Delvaux C., Rentier B., Gershon A. Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J 2007, 26(7):632-638.
20. World Health Organisation. Rubella vaccines. Weekly Epidemiological Report 20, 2000; 75:161-169. Available from: URL: [last accessed 2010 May 25]. http://www.who.int/immunization/wer7520rubella%20_May00_position_paper.pdf.
21. World Health Organisation. Mumps virus vaccines. Weekly Epidemiological Report 7, 2007b;82:50-60. Available from: URL: [last accessed 2010 May 25]. http://www.who.int/wer/2007/wer8207/en/index.html.
22. World Health Organisation. BCG vaccine. Weekly Epidemiological Report 4, 2004; 79:27-38. Available from: URL: [last accessed 2010 May 25]. http://www.who.int/wer/2004/wer7904/en/index.html.
23. Maassab H.F., Bryant M.L. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 1999, 9(4):237-244.
24. World Health Organisation. Rotavirus vaccines. Weekly Epidemiological Report 32, 2007c;82:285-295. Available from: URL: [last accessed 2010 May 25]. http://www.who.int/wer/2007/wer8232/en/index.html.
25. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of Herpes Zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57(RR-5):1-30. Available from: URL: [last accessed 2010 May 25]. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e0515a1.htm.
26. Siegrist C.A. Vaccine immunology. Vaccines 2008, 17-36. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
27. Banatvala J.E., Van Damme P. Hepatitis B vaccine-do we need boosters?. J Viral Hepat 2003, 10(1):1-6.
28. Mills K.H., Ryan M., Ryan E., Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998, 66(2):594-602.
29. Schwarz T.F., Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008, 110(3 Suppl. 1):S1-S10.
30. Gomez P.L., Robinson J.M., Rogalewicz J.A. Vaccine manufacturing. Vaccines 2008, 45-58. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
31. Fraser A., Goldberg E., Acosta C.J., Paul M., Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev 2007, 3. CD001261.
32. Pletz M.W., Maus U., Krug N., Welte T., Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008, 32(3):199-206.
33. Dintzis R.Z. Rational design of conjugate vaccines. Pediatr Res 1992, 32(4):376-385.
34. World Health Organisation. WHO Position Paper on Haemophilus influenzae type b conjugate vaccines. Weekly Epidemiological Report 47, 2006; 81:445-452. Available from: URL: [last accessed 2010 May 25]. http://www.who.int/wer/2006/wer8147/en/index.html.
35. World Health Organisation. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Weekly Epidemiological Report 40, 2002; 77:331-339. Available from: URL: [last accessed 2010 May 25]. http://www.who.int/immunization/wer7740meningococcal_Oct02_position_paper.pdf.
36. Bijker M.S., Melief C.J., Offringa R., van der Burg S.H. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines 2007, 6(4):591-603.
37. McCullers J.A. Evolution, benefits, and shortcomings of vaccine management. J Manag Care Pharm 2007, 13(7 Suppl. B):S2-S6.
38. André F.E. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990, 8(Suppl.):S74-S78.
39. Rogers L.J., Eva L.J., Luesley D.M. Vaccines against cervical cancer. Curr Opin Oncol 2008, 20(5):570-574.
40. Roy P., Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin 2008, 4(1):5-12.
41. Rinaudo C.D., Telford J.L., Rappuoli R., Seib K.L. Vaccinology in the genome era. J Clin Invest 2009, 119(9):2515-2525.
42. Kelly D.F., Rappuoli R. Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv Exp Med Biol 2005, 568:217-223.
43. Brewer J.M. (How) do aluminium adjuvants work?. Immunol Lett 2006, 102(1):10-15.
44. Leroux-Roels G. Unmet needs in modern vaccinology. Adjuvants to improve the immune response. Vaccine 2010.
45. Higgins D., Marshall J.D., Traquina P., Van N.G., Livingston B.D. Immunostimulatory DNA as a vaccine adjuvant. Expert Rev Vaccines 2007, 6(5):747-759.
46. Alderson M.R., McGowan P., Baldridge J.R., Probst P. TLR4 agonists as immunomodulatory agents. J Endotoxin Res 2006, 12(5):313-319.
47. Garçon N., Van Mechelen M., Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. Immunopotentiators in modern vaccines 2006, 161-177. Elsevier Academic Press, London. V. Schijns, D. O'Hagan (Eds.).
48. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
49. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-350.
50. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009, 5(10):705-719.
51. Markowitz L.E., Dunne E.F., Saraiya M., Lawson H.W., Chesson H., Unger E.R. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007, 56(RR-2):1-24.
52. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.-N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
53. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007, 3(4):109-115.
54. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25(39-40):6852-6862.
55. Finlay B.B., McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 2006, 124(4):767-782.
56. Nagy G., Emody L., Pal T. Strategies for the development of vaccines conferring broad-spectrum protection. Int J Med Microbiol 2008, 298(5-6):379-395.
57. Leroux-Roels I., Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 2009, 8(4):401-423.
58. Wipasa J., Riley E.M. The immunological challenges of malaria vaccine development. Expert Opin Biol Ther 2007, 7(12):1841-1852.
59. Klein-Klouwenberg P., Bont L. Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin Dev Immunol 2008, 2008:628963.
60. Siegrist C.A. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 2007, 137(Suppl. 1):S4-S9.
61. Kovaiou R.D., Herndler-Brandstetter D., Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med 2007, 9(3):1-17.
62. Grubeck-Loebenstein B., Della B.S., Iorio A.M., Michel J.P., Pawelec G., Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009, 21(3):201-209.
63. Haynes L., Swain S.L. Why aging T cells fail: implications for vaccination. Immunity 2006, 24(6):663-666.
64. Kang I., Hong M.S., Nolasco H., Park S.H., Dan J.M., Choi J.Y., et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol 2004, 173(1):673-681.
65. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Use of Vaccines and Immune Globulins in Persons with Altered Immunocompetence. MMWR Recomm Rep 1993; 42(RR-4):1-18. Available from: URL: [last accessed 2010 May 25]. http://www.cdc.gov/mmwr/preview/mmwrhtml/00023141.htm.
66. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-15):1-48. Available from: URL: [last accessed 2010 May 25]. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm.
67. Moss W.J., Halsey N.A. Vaccination of human immunodeficiency virus-infected persons. Vaccines 2008, 1417-1430. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
68. Rivas P., Herrero M.D., Puente S., Ramirez-Olivencia G., Soriano V. Immunizations in HIV-infected adults. AIDS Rev 2007, 9(3):173-187.
69. Baena A., Porcelli S.A. Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens 2009, 74(3):189-204.
70. Dietrich J., Doherty T.M. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development. APMIS 2009, 117(5-6):440-457.
71. Aagaard C., Hoang T.T., Izzo A., Billeskov R., Troudt J., Arnett K., et al. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One 2009, 4(6):e5930.
72. Reed S.G., Coler R.N., Dalemans W., Tan E.V., La Cruz E.C., Basaraba R.J., et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 2009, 106(7):2301-2306.
73. Von Eschen K., Morrison R., Braun M., Ofori-Anyinam O., De K.E., Pavithran P., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum Vaccin 2009, 5(7):475-482.
74. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Available from: URL: [Epub ahead of print]. doi:10.1016/S0140-6736(10)60393-5.
75. Martin C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?. Eur Respir J 2005, 26(1):162-167.
76. Rupp R., Bernstein D.I. The potential impact of a prophylactic herpes simplex vaccine. Expert Opin Emerg Drugs 2008, 13(1):41-52.
77. Stanberry L.R. Herpes simples virus vaccines. Vaccines 2008, 1207-1212. Elsevier, New York. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
78. Koelle D.M., Corey L. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 2008, 59:381-395.
79. Gill N., Davies E.J., Ashkar A.A. The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection. Am J Reprod Immunol 2008, 59(1):35-43.
80. Reske A., Pollara G., Krummenacher C., Chain B.M., Katz D.R. Understanding HSV-1 entry glycoproteins. Rev Med Virol 2007, 17(3):205-215.
81. Stanberry L.R., Spruance S.L., Cunningham A.L., Bernstein D.I., Mindel A., Sacks S., et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002, 347(21):1652-1661.
82. Daudel D., Weidinger G., Spreng S. Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev Vaccines 2007, 6(1):97-110.
83. Liniger M., Zuniga A., Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007, 6(2):255-266.
84. Berkley S.F., Koff W.C. Scientific and policy challenges to development of an AIDS vaccine. Lancet 2007, 370(9581):94-101.
85. Lipsitch M., O'Hagan J.J. Patterns of antigenic diversity and the mechanisms that maintain them. J R Soc Interface 2007, 4(16):787-802.
86. Barouch D.H., Liu J., Lynch D.M., O'Brien K.L., La P.A., Simmons N.L., et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 2009, 83(18):9584-9590.
87. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
88. Gandhi R.T., O'Neill D., Bosch R.J., Chan E.S., Bucy R.P., Shopis J., et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27(43):6088-6094.
89. Liu J., Ngai N., Stone G.W., Yue F.Y., Ostrowski M.A. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine 2009, 27(37):5077-5084.
90. Streeck H., Jolin J.S., Qi Y., Yassine-Diab B., Johnson R.C., Kwon D.S., et al. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 2009, 83(15):7641-7648.
91. Betts M.R., Gray C.M., Cox J.H., Ferrari G. Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development. Expert Rev Vaccines 2006, 5(4):505-516.
92. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
93. Limbach K.J., Richie T.L. Viral vectors in malaria vaccine development. Parasite Immunol 2009, 31(9):501-519.
94. Belakova J., Horynova M., Krupka M., Weigl E., Raska M. DNA vaccines: are they still just a powerful tool for the future?. Arch Immunol Ther Exp (Warsz) 2007, 55(6):387-398.
95. Srivastava I.K., Liu M.A. Gene vaccines. Ann Intern Med 2003, 138(7):550-559.
96. Okura Y., Matsumoto Y. Recent advance in immunotherapies for Alzheimer disease: with special reference to DNA vaccination. Hum Vaccin 2009, 5(6):373-380.
97. Wang S., Kennedy J.S., West K., Montefiori D.C., Coley S., Lawrence J., et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008, 26(31):3947-3957.
98. Dery M., Bausch D.G. A DNA vaccine for the prevention of Ebola virus infection. Curr Opin Mol Ther 2008, 10(3):285-293.
99. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196(12):1732-1740.
100. Garcia-Hernandez M.L., Gray A., Hubby B., Klinger O.J., Kast W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008, 68(3):861-869.
101. Iinuma T., Homma S., Noda T., Kufe D., Ohno T., Toda G. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest 2004, 113(9):1307-1317.
102. Rong Y., Jin D., Wu W., Lou W., Wang D., Kuang T., et al. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 2009, 9:191.
103. Dougan M., Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009, 27:83-117.
104. Schadendorf D., Algarra S.M., Bastholt L., Cinat G., Dreno B., Eggermont A.M., et al. Immunotherapy of distant metastatic disease. Ann Oncol 2009, 20(Suppl. 6):vi41-vi50.
105. FDA News release. FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer. FDA. Available from: URL: [last accessed 2010 May 25]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm.
106. Brichard V.G., Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin Biol Ther 2008, 8(7):951-968.
107. Garcia B., Neninger E., de la T.A., Leonard I., Martinez R., Viada C., et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008, 14(3):840-846.
108. Neninger-Vinageras E., de la T.A., Osorio R.M., Catala F.M., Bravo I., Mendoza del P.M., et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(9):1452-1458.
109. Broide D.H. Immunomodulation of allergic disease. Annu Rev Med 2009, 60:279-291.
110. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006, 355(14):1445-1455.
111. Silva C.L., Bonato V.L., dos Santos-Junior R.R., Zarate-Blades C.R., Sartori A. Recent advances in DNA vaccines for autoimmune diseases. Expert Rev Vaccines 2009, 8(2):239-252.
112. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30(11):1728-1736.